AB 2000 California Assembly · 2025-2026 Regular Session

Drug formularies.

Summary
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan or health insurer that provides prescription drug benefits and maintains one or more drug formularies to meet certain criteria for its formularies and the placement of drugs on formularies. This bill would prohibit a health care service plan or health insurer that provides prescription drug benefits and maintains one or more drug formularies from making changes to a formulary during a plan or policy year, except in specified circumstances. If a plan or insurer implements a formulary change requiring an enrollee or insured to change to a different drug in the same drug class during the plan year, the bill would authorize the individual to remain on the previously covered drug for the rest of the plan year if the drug was previously approved for coverage for the individual's medical condition, is appropriately prescribed, and is considered safe and effective for treating that condition, and would require the plan or insurer to notify the individual and their provider no less than 90 days before the change is implemented. The bill would require a plan or insurer, or its pharmacy benefit manager, to report to the appropriate department any changes made to a formulary during a plan or policy year within 30 days of the change being made. The bill would authorize the departments to investigate and take enforcement action against a plan or insurer for noncompliance with the above-described requirements and to impose, after notice and the opportunity for a hearing, administrative penalties, as specified, for a violation of these provisions. The bill would authorize the departments to conduct audits related to these provisions. Because a willful violation of the bill's provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program. Existing law requires a health care service plan that provides prescription drug benefits to maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary nonformulary prescription drug. This bill would define "expeditious process" for the above-described purpose to require a plan to approve authorization within 72 hours for nonurgent requests, or within 24 hours if exigent circumstances exist, of a request for approval of a drug prescription. If the plan fails to meet those requirements, the bill would authorize an enrollee to request, and would require the plan to provide, 90 days of transitional coverage to the enrollee for the previously covered drug. The bill would require the Department of Managed Health Care to utilize existing data and its existing authority to collect data from plans and annually publish on its internet website and submit to the Legislature an aggregated report on information related to requests for approval of a nonformulary drug as described above. The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement. This bill would provide that no reimbursement is required by this act for a specified reason.
Bill status in committee 1 of 4 stages cleared
Introduction
Feb 2026
Committee Review
Floor Vote
Governor
Introduced Feb 17, 2026 Last action May 14, 2026
Maddy AI version diff · 3 comparisons

What changed between versions

03/09/26 - Amended Assembly 04/16/26 - Amended Assembly · 9 edits · Apr 16, 2026
MAJOR
AB 2000 was significantly restructured between the March 9 and April 16, 2026 amendments. The bill dropped its amendment to Section 1367.22 (continuity of coverage for previously approved drugs) and instead added a new mid-year formulary change restriction section (1367.208) with a narrowed prohibition scope, new drug substitution exceptions, a continuity-of-coverage right for enrollees facing same-class drug switches, and 90-day advance notice requirements. It also added a major amendment to Section 1367.24 defining 'expeditious process' timelines (72 hours nonurgent, 24 hours urgent) for nonformulary drug authorization, with a 90-day transitional coverage remedy if plans miss those deadlines, plus new annual reporting and transparency requirements.
SCOPE

The prohibition on mid-year formulary changes was narrowed. The original version prohibited removing a drug, moving it to a higher cost tier, or imposing new utilization management requirements. The amended version narrows the core prohibition to moving a drug to a higher cost tier, while allowing other changes through newly added exceptions.

The bill no longer amends Section 1367.22 (the existing continuity-of-coverage provision that prohibited plans from excluding a drug previously approved for an enrollee's condition). That protection is partially replaced by the new continuity right in Section 1367.208(c), but only applies to same-class drug switches rather than all previously approved drugs.

ELIGIBILITY

New exceptions allow plans to replace a covered drug with another drug in the same class (with cost sharing no higher than before), replace a brand name drug with a generic of the same class or same drug (with lower cost sharing required), and add biosimilar or interchangeable biologic products at equal or lower net cost.

REQUIREMENT

If a plan requires an enrollee to switch to a different drug in the same class mid-year, the enrollee may remain on the previously covered drug for the rest of the plan year if it was previously approved, appropriately prescribed, and considered safe and effective. The plan must notify the enrollee and provider at least 90 days before implementing the change.

If a plan fails to meet the 72-hour or 24-hour authorization timelines, an enrollee may request and the plan must provide 90 days of transitional coverage for the previously covered drug.

The DMHC must use existing data and authority to collect data from plans and annually publish on its website and submit to the Legislature an aggregated report including: number of nonformulary authorization requests, approvals, denials, appeals and outcomes, and independent medical reviews.

DEFINITION

Section 1367.24 now defines 'expeditious process' for nonformulary drug authorization as approval within 72 hours for nonurgent requests or 24 hours if exigent circumstances exist, measured from receipt of the request.

ENFORCEMENT

The Department of Managed Health Care director is now explicitly authorized to investigate and take enforcement action against plans for noncompliance, with penalties subject to notice and opportunity for a hearing. Plans may also submit information about their overall compliance record for consideration in penalty determinations.

FISCAL

The fiscal committee determination changed from 'no' to 'yes,' indicating the bill now has a state fiscal impact requiring fiscal committee review. The state-mandated local program designation is now clearly 'yes.'

Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
11
Key actions
3
Committee
6
Amendments
3
May 14, 2026
Lower · Passed
In committee: Held under submission.
lower
May 13, 2026
Committee
In committee: Set, first hearing. Referred to APPR. suspense file.
lower
Apr 20, 2026
Committee
Re-referred to Com. on APPR.
lower
Apr 16, 2026
Lower · Passed
Read second time and amended.
lower
Apr 15, 2026
Introduced
From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (April 14).
lower
Mar 10, 2026
Committee
Re-referred to Com. on HEALTH.
lower
Mar 9, 2026
Introduced
From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.
lower
Mar 9, 2026
Committee
Referred to Com. on HEALTH.
lower
Feb 18, 2026
Lower · Passed
From printer. May be heard in committee March 20.
lower
1 primary · 0 co-sponsors

Sponsors

Role
Legislator
Party
State
District
P
Photo of Cecilia Aguiar-Curry
Cecilia Aguiar-Curry
DDemocratic
CA
4